Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside tumor cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I enzyme, preventing the re‑ligation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage, triggering apoptosis and cell death in rapidly dividing cancer cells.

The dose of Irinotecan Kabi is individualized and determined by the prescribing oncologist based on factors such as the type of cancer, treatment regimen, patient weight, liver function and prior therapy. No standard dose is provided here; the prescriber will calculate the appropriate amount for each patient.

The safety of Irinotecan in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit to the mother outweighs the unknown risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period thereafter as advised by their physician.

To order Irinotecan Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

The primary alternative to Irinotecan in colorectal cancer regimens is the topoisomerase I inhibitor topotecan, though topotecan is less commonly used for this indication. Compared with oxaliplatin‑based regimens, Irinotecan offers a different toxicity profile, with more pronounced gastrointestinal effects but less peripheral neuropathy. Choice of therapy depends on prior treatment history, patient tolerance and molecular characteristics of the tumor.

Irinotecan Kabi vials should be stored at ambient temperature, preferably below 25 °C, protected from light and moisture. Keep the product in its original packaging until use. Do not freeze. Follow standard aseptic techniques when preparing the intravenous infusion to maintain sterility.

Irinotecan Kabi is administered by intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion schedule (e.g., weekly, bi‑weekly) and total treatment cycle are defined by the treating oncologist based on the specific cancer type, combination partners and patient response.

The most serious risks associated with Irinotecan include severe neutropenia leading to infection, febrile neutropenia, life‑threatening diarrhea that may cause dehydration, intestinal perforation, and rare but severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, fever, persistent diarrhea or abdominal pain, and any allergic symptoms.

Irinotecan Kabi should be avoided in patients with known hypersensitivity to irinotecan or any of its excipients, those with severe hepatic impairment, and individuals with uncontrolled infections. Caution is also advised for patients with pre‑existing severe bone‑marrow suppression or gastrointestinal disorders that could be aggravated by the drug.